8 completed, 1 terminated, 1 unknown. 3 Phase 1, 3 Phase 2, 2 Phase 3, 1 Early Phase 1, 1 Not applicable.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 3 | Completed 3 |
| Phase 2 | 3 | Completed 2, Terminated 1 |
| Phase 3 | 2 | Completed 2 |
| Early Phase 1 | 1 | Unknown 1 |
| Not applicable | 1 | Completed 1 |
Follow gp100 Melanoma Antigen: new trials by email Literature Review of gp100 Melanoma Antigen trials Research Report on gp100 Melanoma Antigen
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Using Silica 12CH to Mitigate the Effects and Symptoms of Silicosis in Brazil Silica 12CH - Silicosis | Early Phase 1 | Unknown | HOHM Foundation | 100 | 2024-03-01 | 2024-02-28 |
| Trial of Indole-3-Carbinol and Silibinin Indole-3-Carbinol, Silibinin, Silibin - Smoking | Phase 1 | Completed | Masonic Cancer Center, University of Minnesota | 21 | 2018-11-29 | 2021-08-11 |
| Tumor and Vaccine Site With a Toll Like Receptor (TLR) Agonist gp100, R848 gel, MAGE-3 - Melanoma | Phase 2 | Completed | M.D. Anderson Cancer Center | 47 | 2010-05-20 | 2021-08-13 |
| Dendritic Cell Vaccination During Lymphoid Reconstruction Autologous Dendritic Cells (DC), Fludarabine, Autologous Lymphocyte Infusion (ALI) - Intraocular Melanoma, Melanoma (Skin) | Phase 1 | Completed | H. Lee Moffitt Cancer Center and Research Institute | 18 | 2006-02-01 | 2014-02-21 |
| Vaccine Therapy With or Without Interleukin-2 After Chemotherapy and an Autologous White Blood Cell Infusion in Treating Patients With Metastatic Melanoma cyclophosphamide, fludarabine phosphate, therapeutic autologous lymphocytes - Recurrent Melanoma, Stage IV Melanoma | Phase 2 | Terminated | National Cancer Institute (NCI) | 58 | 2005-11-01 | 2013-06-06 |
| MDX-010 Antibody, MDX-1379 Melanoma Vaccine, or MDX-010/MDX-1379 Combination Treatment for Patients With Unresectable or Metastatic Melanoma MDX-010 (anti-CTLA4) monoclonal antibody, MDX-1379 (gp100) Melanoma Peptide Vaccine - Melanoma, Metastases | Phase 3 | Completed | Bristol-Myers Squibb | 1783 | 2004-09-01 | 2011-07-11 |
| Vaccine Therapy in Treating Patients With Stage IIC-IV Melanoma gp100 antigen, tyrosinase peptide, recombinant MAGE-3.1 antigen - Ciliary Body and Choroid Melanoma, Medium/Large Size, Ciliary Body and Choroid Melanoma, Small Size | Phase 2 | Completed | University of Southern California | 42 | 2004-05-01 | 2014-05-22 |
| Vaccine Therapy and Sargramostim in Treating Patients With Stage IV Malignant Melanoma tyrosinase peptide, MART-1:27-35 peptide vaccine, gp100 antigen - Recurrent Melanoma, Stage IV Melanoma | Not applicable | Completed | National Cancer Institute (NCI) | 30 | 2000-10-01 | 2013-01-25 |
| Aldesleukin With or Without Vaccine Therapy in Treating Patients With Locally Advanced or Metastatic Melanoma Aldesleukin, gp100 Antigen, Montanide ISA 51 VG - Recurrent Melanoma, Stage IIIA Skin Melanoma | Phase 3 | Completed | National Cancer Institute (NCI) | 185 | 1999-12-01 | 2017-11-20 |
| Vaccine Therapy in Treating Patients With Metastatic Melanoma QS21, IFA (incomplete Freund's adjuvant), p946 - Melanoma (Skin) | Phase 1 | Completed | University of Virginia | 22 | 1996-02-01 | 2014-11-20 |
Melanoma (8) · Neoplasm Metastasis (2) · Uveal Melanoma (2) · Neoplasms (1) · Silicosis (1) · Skin Neoplasms (1) · Smoking (1)
National Cancer Institute (NCI) (3) · Bristol-Myers Squibb (1) · H. Lee Moffitt Cancer Center and Research Institute (1) · HOHM Foundation (1) · M.D. Anderson Cancer Center (1) · Masonic Cancer Center, University of Minnesota (1) · University of Southern California (1) · University of Virginia (1)
United States (10) · Argentina (1) · Belgium (1) · Brazil (1) · Canada (1) · Chile (1) · France (1) · Germany (1) · Hungary (1) · Netherlands (1) · South Africa (1) · Switzerland (1) · United Kingdom (1)
Alastair C Gray, PhD (1) · Craig L. Slingluff, MD (1) · Douglas Schwartzentruber (1) · Jeffrey S. Weber, M.D., Ph.D. (1) · Jeffrey Weber (1) · Michael A. Davies, PHD (1) · Naomi Fujioka, MD (1) · Steven Rosenberg (1) · Svetomir Markovic (1)
PMID 11595689, PMID 12371452, PMID 17296674, PMID 20525992, PMID 21631324, PMID 22694829, PMID 23400564, PMID 23444228, PMID 23942774, PMID 24685414, PMID 25214238, PMID 25649350, PMID 25667295, PMID 26627641, PMID 26700304, PMID 28195659, PMID 28514023, PMID 33774816, PMID 35918725